VertiFlex Announces 150th Patient Enrolled in Superion(TM) IDE Trial

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced that 150 patients have been enrolled in its pivotal IDE clinical trial of the Superion Interspinous Spacer (ISS).

MORE ON THIS TOPIC